Form 4 for MAZE Maze Therapeutics, Inc.
Accepted 2026-01-08 00:00:00 ET · period of report 2026-01-06 · accession 0001555132-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-08 | 2026-01-06+ | MAZE | Sohn Catherine A. | Dir | S - Sale+OE | $39.07 | -29.4K | 0 | -100% | -$1.15M |
| DM | 2026-01-08 | 2026-01-06+ | MAZE | Sohn Catherine A. | Dir | M - OptEx | $10.42 | +29.4K | 2,493 | New | +$306.5K |
| DM | 2026-01-08 | 2026-01-06+ | MAZE | Sohn Catherine A. | Dir | M - OptEx | $0.00 | -29.4K | 3,211 | -90% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-07 | S | D | 26,920 | $39.11 | 0 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive. |
| 2 | Common | Common Stock | 2026-01-07 | M | A | 3,281 | $10.42 | 26,920 | D | — | — | |
| 3 | Common | Common Stock | 2026-01-07 | M | A | 2,895 | $10.42 | 23,639 | D | — | — | |
| 4 | Common | Common Stock | 2026-01-07 | M | A | 20,744 | $10.42 | 20,744 | D | — | — | |
| 5 | Common | Common Stock | 2026-01-06 | S | D | 2,493 | $38.62 | 0 | D | — | — | (F1) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4. |
| 6 | Common | Common Stock | 2026-01-06 | M | A | 2,493 | $10.42 | 2,493 | D | — | — | |
| 7 | Derivative | Stock Option (Right to Buy) | 2026-01-07 | M | D | 3,281 | $0.00 | 5,805 | D | $10.42 · — to 2034-12-08 | 3,281 Common Stock | (F5) The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| 8 | Derivative | Stock Option (Right to Buy) | 2026-01-07 | M | D | 2,895 | $0.00 | 316 | D | $10.42 · — to 2033-03-08 | 2,895 Common Stock | (F3) The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| 9 | Derivative | Stock Option (Right to Buy) | 2026-01-07 | M | D | 20,744 | $0.00 | 0 | D | $10.42 · — to 2031-02-01 | 20,744 Common Stock | (F4) The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024. |
| 10 | Derivative | Stock Option (Right to Buy) | 2026-01-06 | M | D | 2,493 | $0.00 | 3,211 | D | $10.42 · — to 2033-03-08 | 2,493 Common Stock | (F3) The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |